A tale of two variants: Spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa
暂无分享,去创建一个
C. Althaus | R. Neher | E. Hodcroft | C. Williamson | W. Preiser | L. Kaiser | I. Eckerle | H. Spechbach | M. Davies | J. Riou | P. Vetter | R. Lessells | N. Hsiao | F. Jacquerioz | J. Salamun | S. Baggio | M. Reichmuth | T. de Olivera
[1] G. Biele,et al. Estimating infectiousness throughout SARS-CoV-2 infection course , 2021, Science.
[2] M. Suchard,et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.
[3] S. Merler,et al. Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1 , 2021, medRxiv.
[4] T. Ndung’u,et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma , 2021, Nature.
[5] Graham W. Taylor,et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Nature.
[6] T. de Oliveira,et al. New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications , 2021, The New England journal of medicine.
[7] N. G. Davies,et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.
[8] William T. Harvey,et al. Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.
[9] Timothy M. Sykes,et al. Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland , 2021, Epidemics.
[10] Sergei L. Kosakovsky Pond,et al. Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.
[11] M. Shankar-Hari,et al. Virological and serological characterization of critically ill patient with COVID-19 in the UK: a special focus on variant detection , 2021, medRxiv.
[12] D. Moodley,et al. Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant , 2021, medRxiv.
[13] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak , 2021, The Lancet Infectious Diseases.
[14] L. Morris,et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, bioRxiv.
[15] J. Farrar,et al. Increased infections, but not viral burden, with a new SARS-CoV-2 variant , 2021 .
[16] Carl A. B. Pearson,et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.
[17] S. Yerly,et al. SARS-CoV-2 viral load in the upper respiratory tract of children and adults with early acute COVID-19 , 2020, medRxiv.
[18] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[19] C. Faes,et al. Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[20] S. Greenland,et al. Scientists rise up against statistical significance , 2019, Nature.
[21] Yuelong Shu,et al. GISAID: Global initiative on sharing all influenza data – from vision to reality , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[22] Wilco Keulen,et al. Estimating Relative Fitness in Viral Competition Experiments , 2000, Journal of Virology.